Our interest in this case arose from the fact that this case is the first report of a durable, dramatic response to alectinib in a lung adenocarcinoma patient harboring both an EGFR mutation and an ALK rearrangement for the uncommon genomic breakpoint. The gene discussed is EGFR; the disease is lung adenocarcinoma.